IMUNOFAN Dosed Intranasal Spray

IMMUNOMODULATOR IMUNOFAN DOSED INTRANASAL SPRAY  intended for intranasally administration. The advantages of this form of release are ease of use and speed of action. 

Imunofan is synthesized on the basis of the natural peptide hormone of the thymus gland - thymopoietin. Due to the mechanism of action of its prototype, IMUNOFAN is not an immune stimulant, as well as an immunosuppressant. Imunofan has a modulating effect - it returns immunity indicators to the boundaries of reference values. It increases low and reduces the activity of elevated indicators, ensuring the safety of the drug, as well as the effectiveness and balance of the body's immune response.

According to the composition and mechanism of action, there are currently no analogues of IMUNOFAN. Clinical trials and many years of experience in the therapeutic use of the drug confirm that IMUNOFAN is an effective means of correcting the immune status in various disorders.

IMUNOFAN is an innovative drug with an immunomodulatory effect. Created by scientists from the Central Research Institute of the Ministry of Health, it is a synthetic analogue of thymopoietin, a peptide hormone that regulates the functional state of the immune system.

IMUNOFAN launches a cascade of natural processes in the immune system, helping to bring it into a state of physiological balance.- the state when the immune response to foreign agents will be most effective.

The pharmacological effects of IMUNOFAN are based primarily on its ability:

• restore the balance of the redox system of the body;
• to significantly influence the change in the state of the immune system, both in case of its weakening and in case of excessive activity, by regulating its indicators in the direction of normalizing the indicators of the state of the immune system;
• in complex use, it is expressed to increase the effectiveness of basic therapy in a wide range of pathologies, including due to the qualitative originality of the action in relation to multidrug resistance.
  That is why Imunofan is used for the treatment and prevention of acute and chronic diseases, as well as for the correction of disorders in the immune system.

In complex therapy or independently, IMUNOFAN can be used in:

therapy; surgery; pediatrics; urology; oncology; otorhinolaryngology; dermatovenereology; ophthalmology; pulmonology; gynecology.

IMUNOFAN Benefits:

• Effective - more than 25 years on the Russian pharmaceutical market.
• Safe - allowed for children from two years.
• Convenient - three forms of release of the drug.
• International recognition - used in Europe and the CIS.

Main components: arginyl-alpha-aspartyl-lysyl-valyl-tyrosyl-arginine diacetate (as anhydrous and free of acetic acid) - 45 mcg/dose;

Excipients: glycine (5 mg) sodium chloride (0.7 mg), benzalkonium chloride (0.014 mg), disodium edetate (0.007 mg), purified water (up to 0.14 ml)

IMUNOFAN Action:

The drug has an immunoregulatory, detoxifying, hepatoprotective effect and causes inactivation of free radical and peroxide compounds. The pharmacological action is based on the achievement of three main effects: correction of the immune system, restoration of the balance of the body's oxidative-antioxidant reaction and inhibition of multidrug resistance mediated by proteins of the cell's transmembrane transport pump.

The action of the drug begins to develop within 2-3 hours after administration (fast phase) and lasts up to 4 months (medium and slow phases).
During the fast phase (starts after 2-3 hours, duration - up to 2-3 days), the detoxification effect is manifested primarily: the antioxidant defense of the body is enhanced by stimulating the production of ceruloplasmin, lactoferrin, catalase activity; the drug normalizes the level of lipid peroxidation, inhibits the breakdown of cell membrane phospholipids and the synthesis of arachidonic acid, followed by a decrease in the concentration of cholesterol in the blood and the production of inflammatory mediators. With toxic and infectious liver damage, the drug prevents cytolysis, reduces the activity of transaminases and the concentration of bilirubin in the blood serum.
During the middle phase (begins after 2-3 days, duration - up to 7-10 days) there is an increase in the reactions of phagocytosis and the death of intracellular bacteria and viruses.
During the slow phase (begins on the 7-10th day, duration up to 4 months), the immunoregulatory effect of Imunofan is manifested - the restoration of disturbed indicators of cellular and humoral immunity. During this period, there is a normalization of the immunoregulatory index, there is an increase in the production of specific antibodies. The influence of Imunofan on the production of specific antiviral and antibacterial antibodies is equivalent to the action of some therapeutic vaccines. Unlike the latter, the drug does not significantly affect the production of reaginic IgE antibodies (immunoglobulin E) and does not enhance the immediate hypersensitivity reaction. The drug stimulates the formation of IgA (immunoglobulin A) with its congenital deficiency.
Imunofan effectively suppresses multidrug resistance of tumor cells and increases their sensitivity to the action of cytostatic drugs.

IMUNOFAN Indications:

It is used in adults and children over 2 years of age for the prevention and treatment of immunodeficiency and toxic conditions, acute and chronic infectious and inflammatory diseases.

Contraindications:

Hypersensitivity, pregnancy complicated by Rhesus conflict, children under 2 years of age.

Pregnancy and lactation: 

During pregnancy and during breastfeeding, it is used only if the intended benefit to the mother outweighs the potential risk to the fetus and child.

Dosage and administration:

Intranasally. When using the bottle should be held vertically, spray up. Remove the protective cap from the atomizer. Before the first use, fill the dosing pump by pressing the wide rim of the sprayer 3-4 times. Insert the nebulizer into the nasal passage with the head  upright. Press the wide rim of the atomizer once until it stops. One dose of the drug contains 45 mcg of imunofan. The daily dose should not exceed 180 mcg.
In the complex therapy of acute and chronic infectious and inflammatory diseases accompanied by symptoms intoxication and immunodeficiency, imunofan is prescribed 1 dose (45 mcg) in each nasal passage 2 times a day, daily for 10-15 days.

• With opportunistic infections (cytomegalovirus and herpetic infection, toxoplasmosis, chlamydia, pneumocystosis, cryptosporidiosis): 1 dose (45 mcg) in each nasal passage 2 times a day, daily, the course of treatment is 10-15 days. If necessary, it is possible to repeat the course in 2-4 weeks.
• In chronic viral hepatitis and chronic brucellosis: 1 dose (45 mcg) in each nasal passage 1 time per day, daily, course of treatment 10-15 days, to prevent relapse, repeat courses should be carried out after 4-6 months.
• In the treatment regimen for patients with HIV infection: 1 dose (45 mcg) in each nasal passage 1 time per day, daily, for 10-15 days. If necessary, it is possible to repeat the course in 2-4 weeks.
• In the treatment of cancer patients in the scheme of radical combined treatment (chemo-radiation therapy and surgery): 1 dose (45 mcg) in each nasal passage 1 time per day, daily, for 8-10 days before chemo-radiation therapy and surgery, followed by continuation of the course throughout the entire period of treatment.
• In patients with a widespread tumor process (III-IV stages) of various localization in terms of complex or symptomatic therapy: 1 dose (45 mcg) in each nasal passage 1 time per day, daily, for 8-10 days. If necessary, and the presence of pronounced symptoms of toxicosis, it is recommended to repeat the course.

Side effects: allergic reactions to the components of the drug.

Drug interaction: the action of Imunofan does not depend on the production of PGE2 and the administration of the drug is possible in combination with anti-inflammatory (steroidal and non-steroidal) drugs.

Special instructions: as a result of the activation of phagocytosis, a short-term exacerbation of foci of chronic inflammation, supported by the persistence of viral or bacterial antigens, is possible.

Influence on the ability to drive vehicles and mechanisms: The drug does not affect the ability to drive vehicles, mechanisms.

Storage temperature 2℃ to 8℃

Guaranteed authenticity and quality:

100% Original from NPP BIONOKS (Russia)

Patents and sertificates:

The drug contains as an active pharmacological substance a peptide representing a chain of six amino acid residues, the composition and sequence of which are protected by RF patent No. 2062096.

Development and production:

Research and production enterprise BIONOKS was founded in 1991 by a group of scientists led by Doctor of Medical Sciences, inventor of the USSR, laureate of the Prize of the Government of the Russian Federation in the field of science and technology, Professor V.V. Lebedev.

Almost thirty years of experience in using one of the first synthetic peptide drugs IMUNOFAN in various clinical applications, distributing it through the Russian pharmacy network, and after it the experience of therapeutic use of a new generation of regulatory peptides have demonstrated such a wide range of coverage and high clinical efficacy that IMUNOFAN is classified as strategic products. Such a high rating was obtained, among other things, under the influence of joint experience with the participation of scientific specialists of the Federal Security Service of the Russian Federation, which was reflected in the publication of the publication "News of intelligence and counterintelligence" (No. 3-4 [188], 2004), and , in particular, on the official website of the FSB on the Internet.

The purpose of NPP BIONOX is to conduct research and development aimed at developing its own chemical engineering technology to create new generations of synthetic regulatory peptides with specified qualitative effects and selective effects on the body.

To this end, Bionox exchanges scientific experience and provides comprehensive assistance to domestic and foreign pharmaceutical companies in mastering the latest technologies in medicine and veterinary medicine. Bionox is creating subsidiaries and joint ventures to meet the growing clinical demand for NPP BIONOX products, increasing production volumes and expanding the geography of use, first of all, of those peptide drugs that have no alternative in world medicine.

NPP BIONOKS (Russia)